A five-year National Cancer Institute grant will support efforts to identify biomarkers that predict response and relapse in ...

(Nasdaq:APVO), a clinical-stage biotechnology company developing novel multispecific immuno-oncology therapeutics, today announced that ten patients with newly diagnosed acute myeloid leukemia (AML) ...

Dr. Mahmoudjafari asks Dr. Murthy how he weighs frailty, comorbidities, and functional status when choosing initial treatment ...

Research reveals that FDX1 downregulation in acute myeloid leukemia drives resistance to cuproptosis via the ROS/p53/ME1 axis ...

Panelists discuss how fitness assessment has evolved beyond traditional age cutoffs to incorporate comprehensive geriatric assessments, frailty measures, and individualized evaluations, while ...

Aptevo Therapeutics Inc. announced that ten patients with newly diagnosed acute myeloid leukemia (AML) have advanced to allogeneic stem cell transplant following treatment with mipletamig in ...

PureTech Presents Phase 1b Results for LYT-200 in Relapsed/Refractory High-Risk Myelodysplastic Syndromes & Acute Myeloid Leukemia (AML) at ESMO 2026 ...

Acute myeloid leukemia (AML), an aggressive and often fatal blood cancer, has long resisted a class of drugs called proteasome inhibitors, which work well in multiple myeloma. A new study by ...

Please provide your email address to receive an email when new articles are posted on . Patients with AML who had a low ACS10 genetics score had worse survival outcomes than those with a high score.

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...

Notably, ten of 47 (21%) evaluable frontline patients treated with mipletamig in combination with venetoclax and azacitidine (VEN+AZA) proceeded to allogeneic stem cell transplantation, a potentially ...